Symptom free ( · rotator cuff disease
It is very uncertain whether summary of findings: 5 mg/day changes symptom free ( compared with placebo (very low certainty).
1 finding from 1 review
Function ‐ not measured · rotator cuff disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Harms · rotator cuff disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Headache ‐ not reported4 · rotator cuff disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Benefits · rotator cuff disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain ‐ not reported1 · rotator cuff disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptom free with activities of daily living (patient rated) ( · rotator cuff disease
Summary of findings: 1.25 mg/day plus rehabilitation showed no clear difference in symptom free with activities of daily living (patient rated) ( compared with placebo plus rehabilitation (low certainty).
1 finding from 1 review
ACR 50% improvement · patients with rheumatoid arthritis
Abatacept (2 and 10mg/kg) + DMARDs/biologic probably leads to higher ACR 50% improvement compared with placebo + DMARDs/biologic (moderate certainty).
1 finding from 1 review
Pain Visual analog scale Scale from 0 to 100 (lower is better) · patients with rheumatoid arthritis
1 finding from 1 review
Physical function · patients with rheumatoid arthritis
Abatacept (2 and 10mg/kg) + DMARDs/biologic probably leads to higher improvement in physical function (HAQ: greater than 0.3 increase… compared with placebo + DMARDs/biologic (moderate certainty).
1 finding from 1 review
Achievement of low disease activity state (DAS 28 less than 3.2, scale 0‐10) · patients with rheumatoid arthritis
Abatacept (2 and 10mg/kg) + DMARDs/biologic probably leads to higher achievement of low disease activity state (DAS 28 less than 3.2,… compared with placebo + DMARDs/biologic (moderate certainty).
1 finding from 1 review
Total serious adverse events · patients with rheumatoid arthritis
Abatacept (2 and 10mg/kg) + DMARDs/biologic showed no clear difference in total serious adverse events compared with placebo + DMARDs/biologic (moderate certainty).
1 finding from 1 review
Radiographic progression · patients with rheumatoid arthritis
1 finding from 1 review
Long‐term serious adverse events · patients with rheumatoid arthritis
1 finding from 1 review
For outcome · patients with rheumatoid arthritis in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
ACR 50 response at 6 months · patients with rheumatoid arthritis in adults
Summary of findings: leflunomide leads to higher ACR 50 response at 6 months compared with placebo, 6 months (high certainty).
1 finding from 1 review
HAQ change from baseline Scale from: 0 to 3. · patients with rheumatoid arthritis in adults
1 finding from 1 review
Pain change (0‐100 mm VAS) · patients with rheumatoid arthritis in adults
1 finding from 1 review
Radiographic joint changes · patients with rheumatoid arthritis in adults
Summary of findings: leflunomide showed no clear difference in radiographic change (Change in Sharp score) compared with placebo, 6 months (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis in adults
1 finding from 1 review